What is the recommended sequence and choice of therapy for Parkinson disease?

Sequence and Choice of Anti-Parkinson Therapy

Start dopaminergic therapy with levodopa as first-line treatment for most patients, particularly those over 60-65 years or with moderate-to-severe symptoms, while younger patients (<60 years) with mild symptoms may begin with dopamine agonists or MAO-B inhibitors to delay levodopa-related motor complications.

Initial Therapy Selection Algorithm

For Patients ≥60-65 Years or Moderate-to-Severe Symptoms

• Initiate levodopa (carbidopa-levodopa) as first-line therapy 1, 2, 3
• Provides superior symptom control with better tolerability in older adults
• Most patients eventually require levodopa regardless of initial therapy 1
• No evidence that levodopa is toxic to substantia nigra in humans 2

For Patients <60-65 Years with Mild Symptoms

• Consider dopamine agonists (nonergot) or MAO-B inhibitors (selegiline, rasagiline) as initial monotherapy 1, 3, 4
• Delays motor complications but provides less robust symptom control
• Switch to levodopa when symptoms become functionally disabling 1

Critical Decision Points

• Functional impairment severity is the primary driver
• Chronological age matters less than biological age and comorbidities
• Treatment can be delayed if symptoms are truly mild with minimal functional impact 1

Progression to Advanced Therapies

When Oral Medications Fail: The "5-2-1" Rule

Identify candidates for device-aided therapies when patients experience 5:

• 5 doses of levodopa per day
• 2 hours of OFF time daily
• 1 hour of troublesome dyskinesia daily

Second-Line Device-Aided Therapies (DATs)

For severely fluctuating patients with motor complications:

First-Tier Advanced Options (Strongest Evidence)

1. STN-DBS (subthalamic nucleus deep brain stimulation) 5, 3

   • Most extensively studied intervention
   • Large improvements in motor impairment, fluctuations, and dyskinesia
   • Sustained efficacy beyond 15 years
   • GPi-DBS equally effective with minor differences at 3-year follow-up 5

2. Continuous infusion therapies 5, 3

   • Levodopa-carbidopa intestinal gel (LCIG)
   • Continuous subcutaneous apomorphine infusion (CAI)
   • Subcutaneous foslevodopa/foscarbidopa infusion

Sequencing Strategy for DATs

• Less invasive options first: Consider apomorphine infusions initially 6
• Progress to DBS or intestinal infusions if inadequate response
• Choice depends on patient preference, cognitive status, and surgical candidacy

Special Clinical Scenarios

Young Patients with Early Fluctuations (<60 years)

STN-DBS may be considered even with early motor fluctuations (not severe, possibly morning-OFF only) if quality of life is significantly reduced 5

• Improves motor symptoms and quality of life better than best medical therapy
• Requires documented fluctuations (STN-DBS not recommended for non-fluctuating patients) 5
• Caveat: Higher adverse event rate (54.8% vs 44.1% with medical therapy), though most resolve within 24 months 5

Tremor-Dominant Disease

Young tremor patients (<60 years):

• First-line: Dopaminergic agents (though tremor shows inconsistent response) 5
• STN-DBS or GPi-DBS preferred for medication-refractory tremor 5
  • Both targets equally effective for tremor
  • STN-DBS additionally controls dopamine-resistant tremor
  • Long-term efficacy beyond 15 years established
• STN-MRgFUS (focused ultrasound) is alternative for asymmetric tremor (92% reduction unilaterally) but limited to 3-year data 5

Elderly tremor patients (>60 years):

• VIM-MRgFUS can be alternative when DBS contraindicated due to age, multimorbidity, or surgical risk 5
• Particularly suitable for predominantly unilateral tremor
• Warning: VIM targets provide no benefit for akinesia/rigidity 5

Impulse Control Disorders (ICDs)

When patients develop hypersexuality, pathological gambling, binge eating, or compulsive shopping:

• Goal: Reduce/discontinue dopamine agonists and reduce levodopa dose 5
• STN-DBS shows improvement in ICDs (95% of patients improve, mainly through dopamine agonist reduction) 5
• Continuous infusion therapies (LCIG, CAI) improve ICDs by reducing pulsatile dopaminergic stimulation 5
• GPi-DBS less effective for ICDs (insufficient medication reduction) 5

Common Pitfalls to Avoid

1. Delaying levodopa unnecessarily in older patients or those with significant functional impairment due to outdated toxicity concerns 2

2. Missing the window for early DBS in young patients with documented fluctuations who could benefit from improved quality of life 5

3. Choosing VIM targets (thalamic) for younger patients with decades of life expectancy—provides no benefit for progressive akinesia/rigidity 5

4. Attempting STN-DBS in non-fluctuating patients—studies show no significant benefit 5

5. Overlooking preexisting gait impairment before DBS, which may worsen postoperatively 5

6. Ignoring cognitive impairment as contraindication for invasive therapies 5

Adjunctive Therapies Throughout Disease Course

• Rasagiline, zonisamide: Clinically useful as adjunct in early/stable PD 3
• Entacapone, opicapone, safinamide: Clinically useful for motor fluctuations 3
• Amantadine: Clinically useful for dyskinesia 3
• Exercise and physical therapy: Clinically useful throughout disease course; improves gait, balance, reduces falls 3, 4